# Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study

Source: https://onco.cc/key-papers/paper-tracc-clin-cancer-res-2024/  
OnCo record `paper-tracc-clin-cancer-res-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the TRACC trial registered as NCT04050345, in Clinical Cancer Research (2024), chosen as the most cited paper whose own text cites the registry id.

## Summary

Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) with low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest resected CRC cohort to date with tissue-free minimal residual disease (MRD) detection.

Experimental design: TRACC (tracking mutations in cell-free tumor DNA to predict relapse in early colorectal cancer) included patients with stage I to III resectable CRC. Prospective longitudinal plasma collection for ctDNA occurred pre- and postsurgery, post-ACT, every 3 months for year 1 and every 6 months in years 2 and 3 with imaging annually. The Guardant Reveal assay evaluated genomic and methylation signals. The primary endpoint was 2-year recurrence-free survival (RFS) by postoperative ctDNA detection (NCT04050345).

Results: Between December 2016 and August 2022, 1,203 were patients enrolled. Plasma samples (n = 997) from 214 patients were analyzed. One hundred forty-three patients were evaluable for the primary endpoint; 92 (64.3%) colon, 51 (35.7%) rectal; two (1.4%) stage I, 64 (44.8%) stage II, and 77 (53.8%) stage III. Median follow-up was 30.3 months (95% CI, 29.5-31.3). Two-year RFS was 91.1% in patients with ctDNA not detected postoperatively and 50.4% in those with ctDNA detected [HR, 6.5 (2.96-14.5); P < 0.0001]. Landmark negative predictive value (NPV) was 91.2% (95% CI, 83.9-95.9). Longitudinal sensitivity and specificity were 62.1% (95% CI, 42.2-79.3) and 85.9% (95% CI, 78.9-91.3), respectively. The median lead time from ctDNA detection to radiological recurrence was 7.3 months (IQR, 3.3-12.5; n = 9).

Conclusions: Tissue-free MRD detection with longitudinal sampling predicts recurrence in patients with stage I to III CRC without the need for tissue sequencing. The UK TRACC Part C study is currently investigating the potential for ACT de-escalation in patients with undetectable postoperative ctDNA, given the high NPV indicating a low likelihood of residual disease.

Indexed on Europe PMC as PubMed record 38864835 (DOI 10.1158/1078-0432.ccr-24-0226). Its abstract cites the registry id NCT04050345, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Clinical Cancer Research
- Year: 2024
- DOI: 10.1158/1078-0432.ccr-24-0226
- Authors: Slater S, Bryant A, Aresu M, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT04050345 with the most citations, so it is the natural first reading for anyone following the TRACC trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Clin Cancer Res 2024: https://doi.org/10.1158/1078-0432.ccr-24-0226
- PubMed: https://pubmed.ncbi.nlm.nih.gov/38864835/
- Europe PMC: https://europepmc.org/article/MED/38864835
- ClinicalTrials.gov NCT04050345: https://clinicaltrials.gov/study/NCT04050345

## Connected records

- trials: [TRACC](https://onco.cc/trials/tracc/)
- journals: [Clinical Cancer Research](https://onco.cc/journals/clinical-cancer-research/)

---
JSON: https://onco.cc/api/v1/entities/paper-tracc-clin-cancer-res-2024.json